Hereditary hemochromatosis in the post-HFE era
โ Scribed by John K. Olynyk; Debbie Trinder; Grant A. Ramm; Robert S. Britton; Bruce R. Bacon
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 274 KB
- Volume
- 48
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
โฆ Synopsis
Following the discovery of the HFE gene in 1996 and its linkage to the iron overload disorder hereditary hemochromatosis (HH) there have been profound developments in our understanding of the pathogenesis of the biochemical and clinical manifestations of a number of iron overload disorders. This article provides an update of recent developments and key issues relating to iron homeostasis and inherited disorders of iron overload, with emphasis on HFE-related HH, and is based on the content of the American Association for the Study of Liver Diseases Single-Topic Conference entitled "Hemochromatosis: What has Happened
๐ SIMILAR VOLUMES
Homozygosity for the mutation Cys282Tyr in the HFE gene has recently been identified as a cause of hereditary hemochromatosis, a disorder resulting in the inappropriate absorption of iron. Approximately 10% of Caucasians are heterozygous for this mutation; however, the gene frequency in African Amer
Hereditary hemochromatosis (HH) is a common inherited iron overload disorder. The vast majority of patients carry the missense Cys282Tyr mutation of the HFE gene. Hepcidin, the central regulator of iron homeostasis, is deficient in HH, leading to unchecked iron absorption and subsequent iron overloa
## Characteristics of the arthropathy Frequency of arthropathy. The exact proportion of patients who manifest an arthropathy is unknown. Arthropathy in HH has been reported to range from 24 -81% (Table ). Most of these frequency estimates are derived from retrospective case series, where more seve
Hereditary hemochromatosis (HH) is characterized by increased intestinal iron absorption that may result in iron overload. Although phlebotomy is widely practiced, it is poorly tolerated or contraindicated in patients with anemias, severe heart disease, or poor venous access, and compliance can vary